Development of antiviral therapeutics combating coxsackievirus type B3 infection

Enteroviruses comprise highly diverse group of single-stranded positive RNA viruses belonging to Enterovirus genus, Picornaviridae family. They are the most prevalent worldwide highlighted by high resistance environmental cues. normally cause seasonal self-limiting infections, but also known as causative infectious agents encephalitis, myocarditis, poliomyelitis, acute heart failure and sepsis. genetic plasticity contributes widespread epidemics sporadic outbreaks (e. g., D68 71). Type B Coxsackieviruses species is one commonly identified associated predominantly with mild upper respiratory gastrointestinal illnesses. Nevertheless, B3 infection can result in severe myocarditis leading ultimately failure. The pathogenesis Coxsackievirus B3-induced well being mediated both direct damage due viral proteases indirectly via secondary host immune responses. Despite success preventive vaccination some enterovirus infections that allowed control them antiviral for treatment enteroviral particularly myocardial still demand. In addition, no ongoing clinical trials therapy or prevention available. Current strategies mainly aimed stabilize patient condition relieve discomfort condition. It seems relatively small market anti-enteroviral drugs prevents pharma industry from developing new drugs. lifecycle have been extensively studied potential targets drug design identified. aim our review was describe current state field combating emphasizing direct-acting antivirals, albeit paying attention factor-targeting inhibitors (including compounds medicinal plant extracts) well. following categories discussed detail: capsid binders (pleconaril its derivatives), 3C protease (rupintrivir analogs), targeting replication (both nucleoside analogs non-nucleoside inhibitors). Results repurposing screens amiloride, benzerazide, dibucaine fluoxetine discussed.